Welcome to our dedicated page for Arcus Bioscience news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Bioscience stock.
Arcus Biosciences, Inc. (NYSE: RCUS) generates frequent news as a clinical-stage, global biopharmaceutical company advancing investigational therapies for cancer, inflammatory diseases and autoimmune diseases. News about Arcus often centers on clinical trial updates for its lead programs, collaboration developments and corporate financing activities that support its pipeline.
Key oncology news items include data readouts and study milestones for casdatifan, a small-molecule HIF‑2α inhibitor being developed for clear cell renal cell carcinoma (ccRCC). Investors can follow announcements from the ARC‑20 Phase 1/1b study in late-line and early-line ccRCC, the global Phase 3 PEAK‑1 trial in immunotherapy-experienced metastatic ccRCC, and the eVOLVE‑RCC02 Phase 1b/3 study that combines casdatifan with volrustomig in first-line metastatic ccRCC. Updates often highlight progression-free survival, response rates, safety findings and the design of new cohorts or registrational strategies.
Arcus news also covers its broader oncology portfolio, including quemliclustat, a CD73 inhibitor in the PRISM‑1 Phase 3 trial for first-line metastatic pancreatic ductal adenocarcinoma, and the domvanalimab plus zimberelimab combinations in gastrointestinal and lung cancers. Coverage has included positive survival and response data from the Phase 2 EDGE‑Gastric study, as well as the later decision to discontinue the Phase 3 STAR‑221 and EDGE‑Gastric studies after an interim analysis showed no overall survival benefit over standard therapy.
On the inflammation and immunology side, Arcus issues updates on its emerging small-molecule programs targeting MRGPRX2, TNF, CCR6 and CD40L, and an anti‑CD89 antibody program. News may describe preclinical progress, selection of development candidates and plans to enter the clinic in indications such as atopic dermatitis, chronic spontaneous urticaria, rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis and systemic lupus erythematosus.
Corporate and financial news for RCUS includes public equity offerings, amendments to loan facilities, participation in major healthcare and investor conferences, and guidance on cash runway. Readers can use this news page to follow how clinical data, partnership decisions with Gilead Sciences and Taiho Pharmaceutical, and capital-raising activities shape Arcus’s development priorities over time.
Arcus (NYSE:RCUS) outlined 2026 priorities focused on advancing casdatifan (HIF-2a inhibitor) across late-line and first-line ccRCC, with at least three casdatifan data presentations planned in 2026 and a targeted Phase 3 1L study initiation by year-end 2026. The company expects to start a first oral MRGPRX2 antagonist clinical program in 2026 and advance a small-molecule TNF inhibitor into the clinic in late 2026/early 2027. Arcus reports approximately $1 billion cash and investments and expects funding through at least the second half of 2028, assuming a rapid wind down of select studies. Arcus will present at the J.P. Morgan Healthcare Conference on January 14, 2026.
Arcus Biosciences (NYSE:RCUS) announced that CEO Terry Rosen, Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The presentation is scheduled for Wednesday, January 14, 2026 at 3:00 pm PT. A live webcast will be available via the company’s Investors & Media website and a replay will be posted after the event.
Arcus (NYSE:RCUS) will discontinue the Phase 3 STAR-221 study evaluating domvanalimab-based combination in advanced gastric and esophageal cancers after an Independent Data Monitoring Committee determined the trial met futility at a pre-specified interim overall survival analysis.
Arcus will stop STAR-221 and the Phase 2 EDGE-Gastric study, continue patient transition planning, and redirect R&D resources toward casdatifan (HIF-2a inhibitor) and an emerging inflammation & immunology small-molecule portfolio. Arcus reported casdatifan showed robust single-agent activity in >120 patients with late-line ccRCC and plans multiple casdatifan readouts and initiations across 2026, with potential Phase 3 registrational starts in late 2026. Arcus has ~$1B cash and investments, which it expects will fund operations into at least H2 2028.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted equity inducement awards on December 9, 2025. The grants include stock options to purchase 3,600 shares at an exercise price of $25.80 (the December 8, 2025 closing price) and 1,800 restricted stock units. The awards were made under the company's 2020 Inducement Plan pursuant to the NYSE inducement exception (Rule 303A.08) and were approved by the board in January 2020.
Arcus Biosciences (NYSE:RCUS) announced that its management team will participate in two investor conferences in Miami/Coral Gables in early December 2025.
The company will present at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2, 2025 in Coral Gables, FL (fireside chat and 1x1 meetings) at 4:40 p.m. ET, and at Citi’s 2025 Global Healthcare Conference on Wednesday, December 3, 2025 in Miami, FL (fireside chat and 1x1 meetings) at 10:30 a.m. ET. Live webcasts and replays will be available in the company’s Investors & Media section at www.arcusbio.com.
Arcus Biosciences (NYSE: RCUS) priced an underwritten public offering of 13,700,000 common shares at $18.25 per share, for expected gross proceeds of $250 million before underwriting discounts, commissions and expenses. The company granted underwriters a 30-day option to purchase up to 2,055,000 additional shares at the public offering price, less underwriting discounts and commissions.
The offering is expected to close on November 3, 2025, subject to customary closing conditions. A shelf registration became effective on February 28, 2023. Joint bookrunners include Leerink Partners, Goldman Sachs, Cantor, Mizuho and Truist Securities.
Arcus Biosciences (NYSE: RCUS) announced on October 30, 2025 that it has commenced an underwritten public offering of its common stock, with all shares being offered by the company.
The company said it intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares. The offering is subject to market and other conditions, with no assurance of completion, size, or final terms. Leerink Partners and Goldman Sachs are joint book-running managers. The offering relies on a shelf registration that became effective on February 28, 2023, and the preliminary prospectus supplement and prospectus are available free via EDGAR or from the managing banks.
Arcus Biosciences (NYSE:RCUS) reported 3Q2025 results and a pipeline update highlighting clinical momentum for casdatifan, domvanalimab, and quemliclustat. Key clinical readouts: pooled ARC-20 late-line casdatifan mPFS 12.2 months and 18-month landmark PFS 43%; 100 mg casdatifan cohort confirmed ORR 35%. Domvanalimab+zimberelimab+chemo showed median OS 26.7 months in EDGE-Gastric Arm A1. Financials: cash, equivalents and marketable securities $841M at 9/30/2025; revenue $26M in 3Q25; net loss $135M in 3Q25. Multiple Phase 3 readouts and additional ARC-20 data are expected across 2026.
Arcus Biosciences (NYSE:RCUS) and Taiho Pharmaceutical announced Taiho exercised its option to obtain an exclusive license to develop and commercialize casdatifan (AB521) in Japan and certain Asian territories (excluding mainland China) under a 2017 option and license agreement.
Terms include an option exercise payment, additional payments tied to clinical, regulatory and commercialization milestones, and royalties on net sales if products are approved. Casdatifan is an investigational HIF-2α inhibitor being evaluated in a global registrational Phase 3 study (PEAK-1) combining casdatifan with a VEGFR-targeted TKI versus TKI alone in advanced clear cell renal cell carcinoma (ccRCC).
Japan is expected to join PEAK-1 in H1 2026. This marks Taiho's fifth option exercise on an Arcus program and continues the companies' collaboration on casdatifan development.
Arcus Biosciences (NYSE: RCUS) reported first overall survival (OS) results from Arm A1 of the Phase 2 EDGE-Gastric study for first-line treatment of unresectable or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma.
At data cutoff March 3, 2025 (n=41, median follow-up 26.4 months), median OS was 26.7 months (90% CI 18.4, NE), median PFS was 12.9 months (90% CI 9.8, 14.6), and confirmed ORR was 59%. The 24-month OS rate was 50.2%. Safety was consistent with anti-PD-1 plus chemotherapy; immune-mediated adverse events occurred in 22% and infusion reactions in 7%. Results will be presented at ESMO 2025 on October 18 and support the Phase 3 STAR-221 program.
FAQ
What is the current stock price of Arcus Bioscience (RCUS)?
What is the market cap of Arcus Bioscience (RCUS)?
